THD NewsDesk, Mysore: In a recent turn of events, Jubilant Life Sciences has declared that its ancillary, Jubilant Generics launched a Remdesivir antiviral drug for injection for the treatment of COVID-19 in India on the 3rd of August 2020. The cost per vial of 100 mg (lyophilized injection) has been decided at Rs. 4,700 only.
In the name of “JUBI-R”, this drug will be made available to over 1000 hospitals throughout India via its networking and distribution channel.
7 months into the pandemic, many have not still been able to wrap their heads around the ferocity of the Corona Virus. However, with time, we have only come together to put up a stiff battle against the COVID-19. This is the one time when the entire medical, healthcare, and technological industries, numerous institutes and organizations, pharmaceutical companies, brands, NGOs, groups of people to even individuals starting right from the grassroots to the apex, all have seemed to join hands with one motive; to rout out the cataclysmic virus.
Remdesivir is the only drug that acquired Emergency Use Authorization (EUA) by the United States Food and Drug Administration (USFDA) to be utilized in the treatment and medication of the potential or confirmed COVID-19 patients, both children, and adults.
A non-exclusive Licenced Agreement was signed by Jubilant with the Gilead Sciences, Inc addressing the registration, production, and distribution of the investigational drug remdesivir in a total of 127 countries. While, the Drug Controller General of India (DGGI) on the 20th July 2020 approved Jubilant for the produce, manufacture, and distribution of the “JUBI-R” investigational drug remdesivir in the shape of lyophilized injection for restricted emergency use in India.
The initiative to make the drug accessible to all has been started by Jubilant Bhartia Foundation which is essentially a non-profit organization associated with the Jubilant Family. Taking into account the financial drain that the pandemic has exerted on to the public, plunging into the throats of the ones who can barely make ends meet, it is aimed at launching campaigns and programs in India to enhance the approachability and distribution of the drug for the population falling below the Poverty line, and the frontline paramedical workers. It is a noble initiative that could augment the process of treatment and improve the grave ubiquitous situation of the pandemic.
“It gives us immense satisfaction to launch ‘JUBI-R’ as this drug has the potential to save precious lives across the globe. We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet the high demand for the drug in the Indian market and in other countries,” said Shyam Bhartia, Chairman & Managing Director and Hari Bhartia, Co-Chairman, Jubilant Pharma.
Since the announcement, Jubilant Life Sciences shares have gushed up to Rs. 862.30 with a surge of 8.42% on the BSE. The company added, “JUBI-R will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner.”
This Wonder drug could bring a sigh of relief in the times of this epidemic, by curing maximum COVID-19 patients at affordable costs.
